Skip to main content

Table 2 Results of palliative mono- and poly-chemotherapy to advanced salivary gland cancers

From: An overview of the rare parotid gland cancer

 

VNB [32]

VNB/Cisplatin

Cisplatin [33]

Paclitaxel [34]

Mitoxantrone/Cisplatin [35]

Cyclo-phosphamide/Doxorubicin/Cisplatin CAP [36]

Adriamycin/cis-Platinum/Cyclo-phosphamide [37]

Docetaxel [38]

CR

0

3(19%)

3(12%)

0(0%)

0(0%)

3(23%)

3(60%)

2(50%)

PR

4(20%)

4(25%)

1(4%)

8(17·8%)

2(14·3%)

3(23%)

2(40%)

2(50%)

NC

9(45%)

6(37·5%)

 

15(33·3%)

9(64·3%)

   

PD

7(35%)

3(19%)

 

20(44·4%)

3(21·4%)

   

NE

   

2(4·4%)

    

Patients

20

16

25

45

14

13

5

4

  1. VNB: vinorelbine; CR: complete response; PR: partial response; NC: no change (stable disease); PD: progressive disease; NE: not evaluable